Articles

Harmonizing technological innovation and a platform approach in biomanufacturing can reduce
time and cost barriers to produce stable, high-expressing antibody-based therapeutics

A Streamlined Platform Process to Accelerate Biotherapeutics from Gene to Clinic

By integrating QbD into the development process, organizations can achieve robust manufacturing processes, regulatory compliance, and commercial success.

Quality by Design (QbD) for Biologics: A CDMO's Perspective

In vitro transcription (IVT) is often used to make mRNA, and in co-transcriptional capping an analog cap can be used to cap the mRNA. This paper reviews the recent history of capping analogs in addition to a state-of-the-art approach to improve protein expression. 

Capping and Manufacturing Strategies for Increasing mRNA Potency and Reducing Costs

Harness High-Quality PBPK Modeling to Enhance Preclinical and Clinical Readiness

Powering Drug Development With Advanced Retrosynthetic Analysis Tools

Early Solid Form Screening to Guide Drug Substance through Drug Product Development

Leveraging Advanced Analytical Tools to De-Risk Pharmaceutical Development (Sept 2024)

Accelerating Small Molecule Advancements: The Power of Collaboration Between CDMOs and Biotechs  (Sept 2024)

Drug stability impacts efficacy and safety. Choosing the right packaging is crucial. This paper outlines key factors affecting stability and provides packaging guidelines.

Enhancing Drug Stability via Packaging Choice

Ecolab is looking to the future with new opportunities to partner with Pharma for critical solutions to support drug development and manufacturing.

All Whitepapers